Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

Arthritis Research and Therapy

Volumn 8, Issue 6, 2006, Pages

  Kristensen, Lars Erik ^a   Saxne, Tore ^a   Nilsson, Jan Åke ^a   Geborek, Pierre ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

AGE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; SWEDEN;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PATIENT COMPLIANCE; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SWEDEN;

EID: 36749002002     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2084     Document Type: Article

References (25)

1. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliot MJ, Woody JN, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al.: Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen J, Weisman M, Emery P, Feldmann M, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343 1594-1602.
4. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997, 337:141-147.
5. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al.: Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann intern Med 1999, 130:478-486.
6. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 2000, 343:1586-1593.
7. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
8. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:353-363.
9. Klareskog L, van der HD, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004, 363:675-681.
10. Zink A, Listing JD, Kary S, Ramlau P, Stoyanova-Scholz M, babinsky K, von Hineuber U, Gromnica-Ihle E, Wassenberg S, Antoni C, et al.: Treatment continuation in patients receiving biologics or conventional DMARD therapy. Ann Rheum Dis 2005, 64 1274-1279.
11. Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798.
12. Geborek P, Nitelius E, Noltorp S, Petri H, Jacobsson L, Larsson L, Saxne T, Leden I: Population based studies of biologic antirheumatic drug use in southern Sweden. Comparison with pharmaceutical sales. Ann Rheum Dis 2005, 64:1805-1807.
13. Van Riel PLCM, van Gestel AM, Scott DL on behalf of the EULAR standing committee for international clinical studies including therapeutic trials: The EULAR Handbook of Clinical Assessment in Rheumatoid Arthritis Alpen an den Rijn, The Netherlands: Van Zuiden Communications; 2000.
14. Gomez-Reino JJ, Carmona L, the BIOBADASER Group: Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8:R29.
15. Sokka T, Pincus T: Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet the inclusion criteria for most recent trials of American College of Rheumatology criteria for remission. J Rheumatol 2003, 30:1138-1146.
16. Hanauer SB: Review article: safety of infliximab in clinical trials Aliment Pharmacol Ther 1999, 13:16-22.
17. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Eng J Med 2003, 348 601-608.
18. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH: Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001, 60:729-735.
19. Scallon B, Cai A, Soowski N: Binding and functional comparison of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
20. Ziolkowska M, Maslinski W: Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:267-273.
21. Lugering A, Schmidt M, Lugering N: Infliximab induces apoptosis in monocytes from patients with active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121 1145-1157.
22. Utley M, Gallivan S, Young A, Cox N, Davies P, Dixey J, Emery P, Gough A, James D, Prouse P, et al.: Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies. Rheumatology 2000, 39:1-2.
23. Pincus T, Sokka T: How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 2001, 15:139-170.
24. Wolfe F, Michaud K, DeWitt EM: Why results of clinical trials and observational studies of antitumor necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004, 63:iI13-ii17.
25. Pincus T, Sokka T: Should Contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004, 63:iI32-ii39.